GARD®air.

The world’s first in vitro test for the prediction of chemical respiratory sensitizers

Sensitizing chemicals may induce sensitization of the respiratory tract, leading to symptoms known as occupational asthma.

GARDair enables not only development of safe products but also preventative measures – something that has not been feasible before.

There is currently a great need for tests in several different industries. GARDair, which was launched in the autumn of 2018, makes it possible to predict the risk of causing hypersensitivity with high reliability.

Using GARDair, it is possible not only to develop better and safer products, but also to be able to offer employees a safe production and work environment.

More information

Find out more about the GARD tests in our product sheets or let our specialists explain the technology more thoroughly to you.

DOWNLOAD PRODUCT FACTS

CONTACT OUR SPECIALISTS

GARDair at a glance

  • Safety assessment of respiratory sensitizers
  • Human dendritic-like cell line
  • Genomic biomarker signature monitoring innate immune function, dendritic cell activation and Th2 polarisation
  • Bioinformatic model
  • ~ 90% accuracy on in-house validated data

Application areas

  • Industrial chemicals
  • Pharmaceutical
  • Cosmetics
  • Agro Chemicals
  • Occupational groups in manufacturing are particularly exposed (occupational health).

EU backs development

The development of GARD®air was funded by the EU research initiative Horizon 2020. In 2019 the project was chosen by the EU for a special campaign on how EU funds are used to create jobs and growth.

Information related to GARDair

Subscribe


Prenumerera